DaVita (DVA) Projected to Announce Quarterly Earnings on Tuesday

DaVita (NYSE:DVA) is expected to be issuing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $3.88 per share and revenue of $3.4963 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.00 earnings per share. On average, analysts expect DaVita to post $15 EPS for the current fiscal year and $18 EPS for the next fiscal year.

DaVita Stock Down 0.0%

Shares of NYSE DVA opened at $240.00 on Monday. DaVita has a 52 week low of $101.00 and a 52 week high of $244.49. The business’s 50 day moving average price is $217.76 and its 200 day moving average price is $173.57. The firm has a market cap of $15.41 billion, a P/E ratio of 22.26, a P/E/G ratio of 0.79 and a beta of 0.88.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is owned by insiders.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently modified their holdings of the business. Caitlin John LLC acquired a new position in DaVita in the 4th quarter worth about $34,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the second quarter valued at approximately $43,000. Kestra Advisory Services LLC purchased a new stake in shares of DaVita in the fourth quarter valued at approximately $45,000. iSAM Funds UK Ltd acquired a new position in shares of DaVita during the 3rd quarter worth approximately $46,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of DaVita during the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. UBS Group raised their target price on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Barclays upped their price target on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Finally, Truist Financial boosted their price objective on DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $216.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.